Viracta Therapeutics, Inc. - VIRX STOCK NEWS

Viracta Therapeutics (Nasdaq: VIRX) presented new preclinical data on vecabrutinib, a reversible inhibitor of Bruton's tyrosine kinase (BTK), at the 2021 ASH Annual Meeting. Key findings from the oral presentation indicate vecabrutinib enhances the efficacy and safety of CART19 cell therapy, potentially leading to improved long-term responses in hematological malignancies. Additionally, a poster presentation highlighted vecabrutinib's effectiveness in reducing symptoms of cGVHD. The company aims to explore clinical development options for combining vecabrutinib with CART19.

Viracta Therapeutics (Nasdaq: VIRX) has presented final data from its Phase 1b/2 trial of Nana-val for relapsed/refractory EBV+ lymphoma at the 2021 ASH Annual Meeting. The trial included 55 patients, showing a 40% overall response rate (ORR) and a 19% complete response (CR) rate. Notably, the median duration of response (DoR) was 10.4 months, indicating promising durability. Nana-val was generally well tolerated. The company highlighted the trial's potential to address unmet needs in EBV-associated cancers and plans to advance into the NAVAL-1 registration-enabling study.

Viracta Therapeutics (Nasdaq: VIRX) announced that the FDA has granted orphan drug designation for its oral product candidate, nanatinostat and valganciclovir (Nana-val), aimed at treating Epstein Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL). DLBCL represents about 25% of non-Hodgkin lymphoma cases in the U.S. The orphan drug status facilitates development, offering benefits like tax credits and market exclusivity. Currently, Viracta is conducting the NAVAL-1 trial to evaluate Nana-val's effectiveness in EBV+ DLBCL patients, with enrollment sites open in the U.S., Europe, and Asia.

Viracta Therapeutics (Nasdaq: VIRX) announced its Q3 2021 financial results, highlighting notable advancements, including the initiation of an EBV-positive solid tumor trial and reacquisition of Nana-val’s rights in China. The company ended the quarter with approximately $111 million in cash and is on track to exceed $100 million by year-end 2021. Key clinical updates include the expansion of the NAVAL-1 trial and positive preliminary results for Nana-val in EBV-positive lymphoma. Viracta is positioned to advance its clinical trials and maintain strong financial health into 2024.

Viracta Therapeutics (Nasdaq: VIRX) has secured a $50.0 million credit facility from Silicon Valley Bank and Oxford Finance. This facility replaces a previous $15.0 million loan agreement, refinancing $5.0 million of existing debt. The new credit line allows for additional tranches of $20.0 million and $25.0 million, providing the company with non-dilutive financing and enhancing operational flexibility. The funding is expected to support upcoming clinical trials and advance the company's vaccine technology targeting virus-associated cancers.

Viracta Therapeutics (Nasdaq: VIRX) has announced the acceptance of three abstracts for presentation at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. This includes two oral presentations on the final results of their Phase 1b/2 trial for EBV positive lymphoma and the application of vecabrutinib in CAR T cell therapies, along with a poster presentation on vecabrutinib's efficacy in a murine model of graft-versus-host disease. This recognition highlights the innovative progress in Viracta's therapeutic pipeline.

Viracta Therapeutics (NASDAQ: VIRX) is set to present at multiple investor conferences in November 2021. Key events include:

• Credit Suisse 30th Annual Healthcare Conference: Nov 8-12, Presentation on Nov 11 at 1:50 PM ET.
• Jefferies London Healthcare Conference: Nov 16-17, Presentation on Nov 17 at 10:40 AM GMT.
• Piper Sandler 33rd Annual Healthcare Conference: Nov 29-Dec 2, Presentation on Nov 22.
• Evercore ISI 4th Annual HealthCONx Conference: Nov 29-Dec 2, Presentation on Dec 2 at 3:55 PM ET.

Webcasts will be available on their website.

Viracta Therapeutics (Nasdaq: VIRX) has initiated a Phase 1b/2 trial targeting EBV-positive recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) and other EBV-positive solid tumors. The trial will assess the safety and preliminary efficacy of the oral combination of nanatinostat and valganciclovir (Nana-val) alone and with pembrolizumab. The study aims to establish the recommended Phase 2 dose and evaluate overall response rates in up to 60 patients. Viracta's innovative approach shows promise for patients with limited treatment options.

Viracta Therapeutics, a precision oncology firm focusing on virus-associated malignancies, will present at multiple upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will feature an on-demand presentation available from September 13, 2021. Following this, Viracta will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2021, at 4:35 PM ET, and the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 8:40 AM ET. Details and webcasts are accessible through their investor relations website.